198 related articles for article (PubMed ID: 29062340)
1. Biochemical markers of mineral bone disorder in South African patients on maintenance haemodialysis.
Waziri B; Duarte R; Naicker S
Afr Health Sci; 2017 Jun; 17(2):445-452. PubMed ID: 29062340
[TBL] [Abstract][Full Text] [Related]
2. Lower serum fibroblast growth factor-23 levels may suggest malnutrition in maintenance haemodialysis patients.
Mizuiri S; Nishizawa Y; Yamashita K; Ono K; Oda M; Usui K; Shigemoto K
Nephrology (Carlton); 2014 Sep; 19(9):568-73. PubMed ID: 24947687
[TBL] [Abstract][Full Text] [Related]
3. Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients.
Pietrzyk B; Wyskida K; Ficek J; Kolonko A; Ficek R; Więcek A; Olszanecka-Glinianowicz M; Chudek J
Int Urol Nephrol; 2019 Mar; 51(3):519-526. PubMed ID: 30584645
[TBL] [Abstract][Full Text] [Related]
4. Posterior urethral valves: Metabolic consequences in a cohort of patients.
Sarhan O; Nakshabandi Z; Alghanbar M; Alotay A; Sherif I; Whitehead C; El-Husseini A
J Pediatr Urol; 2015 Aug; 11(4):216.e1-6. PubMed ID: 26096436
[TBL] [Abstract][Full Text] [Related]
5. Secondary hyperparathyroidism among Nigerians with chronic kidney disease.
Gimba ZM; Abene EE; Agbaji OOO; Agaba EI
Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972
[TBL] [Abstract][Full Text] [Related]
6. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD.
Ureña-Torres P; Metzger M; Haymann JP; Karras A; Boffa JJ; Flamant M; Vrtovsnik F; Gauci C; Froissart M; Houillier P; Stengel B;
Am J Kidney Dis; 2011 Oct; 58(4):544-53. PubMed ID: 21803465
[TBL] [Abstract][Full Text] [Related]
7. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
[TBL] [Abstract][Full Text] [Related]
8. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephron Clin Pract; 2008; 110(1):c58-65. PubMed ID: 18724068
[TBL] [Abstract][Full Text] [Related]
9. Correlates of parathyroid hormone concentration in hemodialysis patients.
Li J; Molnar MZ; Zaritsky JJ; Sim JJ; Streja E; Kovesdy CP; Salusky I; Kalantar-Zadeh K
Nephrol Dial Transplant; 2013 Jun; 28(6):1516-25. PubMed ID: 23348879
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic accuracy study comparing total alkaline phosphatase with intact parathyroid hormone 1-84 for the diagnosis of high turnover renal osteodystrophy in chronic renal failure on hemodialysis].
Rojas González AM; Opazo Valenzuela M; Muñoz Navarro S
Medwave; 2014 Sep; 14(8):e6014. PubMed ID: 25340338
[TBL] [Abstract][Full Text] [Related]
11. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.
Tangri N; Wagner M; Griffith JL; Miskulin DC; Hodsman A; Ansell D; Naimark DM
Am J Kidney Dis; 2011 Mar; 57(3):415-21. PubMed ID: 21131115
[TBL] [Abstract][Full Text] [Related]
12. Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort.
Jean G; Lafage-Proust MH; Souberbielle JC; Lechevallier S; Deleaval P; Lorriaux C; Hurot JM; Mayor B; Mehdi M; Chazot C
PLoS One; 2018; 13(6):e0199140. PubMed ID: 29912988
[TBL] [Abstract][Full Text] [Related]
13. Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients.
Moore C; Yee J; Malluche H; Rao DS; Monier-Faugere MC; Adams E; Daramola-Ogunwuyi O; Fehmi H; Bhat S; Osman-Malik Y
Clin J Am Soc Nephrol; 2009 Sep; 4(9):1484-1493. PubMed ID: 19713297
[TBL] [Abstract][Full Text] [Related]
14. Seasonal variation of serum 25-hydroxyvitamin D and parameters of bone and mineral disorder in dialysis patients.
Kleine CE; Obi Y; Streja E; Hsiung JT; Park C; Holick MF; Kalantar-Zadeh K
Bone; 2019 Jul; 124():158-165. PubMed ID: 30858148
[TBL] [Abstract][Full Text] [Related]
15. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
[TBL] [Abstract][Full Text] [Related]
16. Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort.
Lamina C; Kronenberg F; Stenvinkel P; Froissart M; Forer L; Schönherr S; Wheeler DC; Eckardt KU; Floege J
Nephrol Dial Transplant; 2020 Mar; 35(3):478-487. PubMed ID: 31006013
[TBL] [Abstract][Full Text] [Related]
17. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
18. [Circulating bone turnover markers and their relationships in hemodialysis patients with vitamin D deficiency].
Kulicki P; Żebrowski P; Sokalski A; Klatko W; Birecka M; Mieczkowski M; Niemczyk S; Małyszko J; Matuszkiewicz-Rowińska J
Wiad Lek; 2019; 72(11 cz 2):2202-2209. PubMed ID: 31860837
[TBL] [Abstract][Full Text] [Related]
19. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
